Cover Image
市場調查報告書

中度疼痛的開發中產品分析

Moderate Pain - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 255979
出版日期 內容資訊 英文 93 Pages
訂單完成後即時交付
價格
Back to Top
中度疼痛的開發中產品分析 Moderate Pain - Pipeline Review, H2 2015
出版日期: 2015年09月30日 內容資訊: 英文 93 Pages
簡介

中度疼痛是指非極度嚴重的疼痛。主要症狀雖然依不同的疾病、障礙或症狀而不同,但最常見為刺痛/隱隱作病或像發熱般的疼痛。如果是皮膚表面的疼痛則是從表皮經由神經細胞到達脊髓的電氣般刺激,並以此為契機會連動發生各種現象。主要的治療法有非類固醇消炎劑(NSAID),及其他的止痛藥等。

本報告提供全球各國治療中度疼痛用的開發中產品開發情形相關分析,提供產品開發·上市的最新趨勢,及臨床實驗各階段的產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

中度疼痛概要

治療藥的開發

  • 中度疼痛開發中產品:概要
  • 中度疼痛開發中產品:比較分析

各企業開發中的中度疼痛治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

中度疼痛治療藥:開發中的產品的一覽(各企業)

中度疼痛治療藥的開發企業

  • Nektar Therapeutics
  • Egalet Corporation
  • Laboratorios Del Dr. Esteve S.A.
  • 興和
  • Pain Therapeutics, Inc.
  • Pfizer Inc.
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Acura Pharmaceuticals, Inc.
  • Elite Pharmaceuticals, Inc.
  • INSYS Therapeutics, Inc.
  • Phosphagenics Limited
  • Trevena, Inc.
  • QRxPharma Limited
  • KemPharm, Inc.
  • Relmada Therapeutics, Inc.
  • ChironWells GmbH

中度疼痛:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 分子類別

藥物簡介

  • oxycodone ER(持續放出/徐放)
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • oxycodone +naltrexone
  • dexketoprofen trometamol+tramadol hydrochloride
  • (oxycodone hydrochloride+naltrexone hydrochloride) ER
  • K-103IP
  • 嗎啡+oxycodone
  • benzhydrocodone hydrochloride
  • morphine sulfate ER
  • NKTR-181
  • celecoxib+tramadol hydrochloride
  • oxymorphone hydrochloride
  • PTI-202
  • PTI-721
  • oxycodone ER
  • levorphanol tartrateER
  • HS-731
  • TRV-734
  • NKTR-194
  • buprenorphine hydrochlorideER
  • HS-731
  • ELS-130
  • buprenorphine hydrochloride
  • ketorolac tromethamine
  • oxycodone +普拿疼 (Acetaminophen)
  • hidoromorufonIR
  • 硫酸嗎啡IR
  • oxymorphoneIR
  • tramadol hydrochlorideIR
  • 美沙酮IR

中度疼痛治療藥:開發中產品的最新趨勢

中度疼痛治療藥:暫停開發的產品

中度疼痛治療藥:開發中止的產品

中度疼痛相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿(全7件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC6976IDB

Summary

Global Markets Direct's, 'Moderate Pain - Pipeline Review, H2 2015', provides an overview of the Moderate Pain's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Moderate Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Pain and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Moderate Pain
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Moderate Pain and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Moderate Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Moderate Pain pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Moderate Pain
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Moderate Pain pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Moderate Pain Overview
  • Therapeutics Development
    • Pipeline Products for Moderate Pain - Overview
    • Pipeline Products for Moderate Pain - Comparative Analysis
  • Moderate Pain - Therapeutics under Development by Companies
  • Moderate Pain - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Moderate Pain - Products under Development by Companies
  • Moderate Pain - Companies Involved in Therapeutics Development
    • A. Menarini Industrie Farmaceutiche Riunite Srl
    • Amorsa Therapeutics Inc.
    • Charleston Laboratories, Inc.
    • Egalet Corporation
    • Elite Pharmaceuticals, Inc.
    • KemPharm, Inc.
    • Laboratorios Del Dr. Esteve S.A.
    • Lumosa Therapeutics Co., Ltd.
    • Nektar Therapeutics
    • Pacira Pharmaceuticals, Inc.
    • Pain Therapeutics, Inc.
    • Pfizer Inc.
    • Purdue Pharma L.P.
    • Relmada Therapeutics, Inc.
    • Teva Pharmaceutical Industries Limited
    • Trevena, Inc.
  • Moderate Pain - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (benzhydrocodone hydrochloride + acetaminophen) IR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (celecoxib + tramadol hydrochloride) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (dexketoprofen + tramadol hydrochloride) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (hydrocodone bitartrate + acetaminophen) IR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (naltrexone hydrochloride + oxycodone hydrochloride) SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (oxycodone hydrochloride + naltrexone hydrochloride) ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • buprenorphine hydrochloride ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CL-108 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CLH-10 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CLH-5 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Egalet-003 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ketamine hydrochloride ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • levorphanol tartrate ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-1001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • meloxicam ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • morphine sulfate ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NKTR-181 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OLT-1177 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • oxycodone hydrochloride ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • oxycodone hydrochloride ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TRV-734 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • V-116517 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Moderate Pain - Recent Pipeline Updates
  • Moderate Pain - Dormant Projects
  • Moderate Pain - Discontinued Products
  • Moderate Pain - Product Development Milestones
    • Featured News & Press Releases
      • Mar 04, 2014: KemPharm Expands Global Intellectual Property Estate for KP201
      • Feb 20, 2014: Egalet Receives Fast Track Designation for Egalet-001
      • Feb 20, 2014: Egalet Receives Fast Track Designation for Egalet-002 for Moderate to Severe Pain
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Moderate Pain, H2 2015
  • Number of Products under Development for Moderate Pain - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Moderate Pain - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2015
  • Moderate Pain - Pipeline by Amorsa Therapeutics Inc., H2 2015
  • Moderate Pain - Pipeline by Charleston Laboratories, Inc., H2 2015
  • Moderate Pain - Pipeline by Egalet Corporation, H2 2015
  • Moderate Pain - Pipeline by Elite Pharmaceuticals, Inc., H2 2015
  • Moderate Pain - Pipeline by KemPharm, Inc., H2 2015
  • Moderate Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2015
  • Moderate Pain - Pipeline by Lumosa Therapeutics Co., Ltd., H2 2015
  • Moderate Pain - Pipeline by Nektar Therapeutics, H2 2015
  • Moderate Pain - Pipeline by Pacira Pharmaceuticals, Inc., H2 2015
  • Moderate Pain - Pipeline by Pain Therapeutics, Inc., H2 2015
  • Moderate Pain - Pipeline by Pfizer Inc., H2 2015
  • Moderate Pain - Pipeline by Purdue Pharma L.P., H2 2015
  • Moderate Pain - Pipeline by Relmada Therapeutics, Inc., H2 2015
  • Moderate Pain - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
  • Moderate Pain - Pipeline by Trevena, Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Moderate Pain Therapeutics - Recent Pipeline Updates, H2 2015
  • Moderate Pain - Dormant Projects, H2 2015
  • Moderate Pain - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Moderate Pain, H2 2015
  • Number of Products under Development for Moderate Pain - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top